Equal Em­ploy­ment Op­por­tu­ni­ty Com­mis­sion brings No­vo Nordisk to court over age dis­crim­i­na­tion case

A 62-year-old obe­si­ty care spe­cial­ist ac­cused No­vo Nordisk of age dis­crim­i­na­tion when she got passed by for a lat­er­al trans­fer back in 2018, re­sult­ing in one dis­trict man­ag­er los­ing his job, ac­cord­ing to a com­plaint.

Three years lat­er, the em­ploy­ee still hasn’t been trans­ferred — and now the US Equal Em­ploy­ment Op­por­tu­ni­ty Com­mis­sion (EEOC) is on the case.

The EEOC filed a com­plaint against No­vo Nordisk in New Jer­sey fed­er­al court on Mon­day, seek­ing re­lief for Deb­o­rah Hunter, a Scotts­dale, AZ woman who’s been an obe­si­ty care spe­cial­ist at the com­pa­ny since 2015.

In 2018, Hunter was as­signed to cov­er the Phoenix area, vis­it­ing health­care providers to pro­mote No­vo Nordisk’s weight loss drug. That same month, she ap­plied for a trans­fer to Flagstaff, as most of those clients were lo­cat­ed near her home in the Scotts­dale area.

Af­ter in­ter­view­ing for the role, a dis­trict man­ag­er al­leged­ly told Hunter that he want­ed some­one who was go­ing to be in the po­si­tion “long term,” and se­lect­ed a 33-year-old for the job.

Ac­cord­ing to the EEOC’s com­plaint, No­vo Nordisk con­duct­ed an in­ter­nal in­ves­ti­ga­tion and found that the man­ag­er had vi­o­lat­ed the com­pa­ny’s equal em­ploy­ment op­por­tu­ni­ty & an­ti-ha­rass­ment pol­i­cy. Even so, Hunter was nev­er of­fered the trans­fer, plain­tiffs claim.

“The un­found­ed stereo­type that old­er work­ers are less valu­able or less com­mit­ted to an or­ga­ni­za­tion’s long-term goals and strat­e­gy should play no role in em­ploy­ment de­ci­sions,” EEOC tri­al at­tor­ney Edu­min Cor­rales said in a news re­lease.

In ad­di­tion to re­lief for Hunter, the plain­tiffs are re­quest­ing a court or­der that bars No­vo Nordisk from age dis­crim­i­na­tion, and re­quires the com­pa­ny to in­sti­tute and car­ry out “poli­cies, prac­tices, and pro­grams which pro­vide equal em­ploy­ment op­por­tu­ni­ties for in­di­vid­u­als 40 years of age and old­er.”

No­vo Nordisk has not re­spond­ed to a re­quest for com­ment.

This marks the lat­est in a string of age dis­crim­i­na­tion cas­es against phar­ma com­pa­nies. In Sep­tem­ber, two for­mer sales rep­re­sen­ta­tives filed a class ac­tion suit against Eli Lil­ly af­ter they ap­plied to work for the com­pa­ny sev­er­al times, but nev­er made it past the first in­ter­view stage. The plain­tiffs al­leged that Eli Lil­ly doesn’t post sales rep­re­sen­ta­tive jobs in its di­a­betes and pri­ma­ry care busi­ness units pub­licly, rather fill­ing the roles with in­terns un­til there are none left avail­able.

Last June, a for­mer As­traZeneca em­ploy­ee filed a law­suit claim­ing that she was fired for her age and her re­fusal to pro­mote drugs that weren’t FDA ap­proved. And in 2018, Te­va was forced to pay more than $6 mil­lion in dam­ages in an age dis­crim­i­na­tion law­suit.

Scoop: Boehringer qui­et­ly shut­ters a PhII for one of its top drugs — now un­der re­view

Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.

The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.

A spokesperson for the company tells Endpoints:

Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fed­er­al judge de­nies Bris­tol My­er­s' at­tempt to avoid Cel­gene share­hold­er law­suit

Some Celgene shareholders aren’t happy with how Bristol Myers Squibb’s takeover went down.

On Friday, a New York federal judge ruled that they have a case against the pharma giant, denying a request to dismiss allegations that it purposely slow-rolled Breyanzi’s approval to avoid paying out $6.4 billion in contingent value rights (CVR).

When Bristol Myers put down $74 billion to scoop up Celgene back in 2019, liso-cel — the CAR-T lymphoma treatment now marketed as Breyanzi — was supposedly one of the centerpieces of the deal. After going back and forth on negotiations for about six months, BMS put $6.4 billion into a CVR agreement that required an FDA approval for Zeposia, Breyanzi and Abecma, each by an established date.

Alex­ion puts €65M for­ward to strength­en its po­si­tion on the Emer­ald Isle

Ireland has been on a roll in 2022, with several large pharma companies announcing multimillion-euro projects. Now AstraZeneca’s rare disease outfit Alexion is looking to get in on the action.

Alexion on Friday announced a €65 million ($68.8 million) investment in new and enhanced capabilities across two sites in the country, including at College Park in the Dublin suburb of Blanchardstown and the Monksland Industrial Park in the central Irish town of Athlone, according to the Industrial Development Agency of Ireland.

State bat­tles over mifepri­s­tone ac­cess could tie the FDA to any post-Roe cross­roads

As more than a dozen states are now readying so-called “trigger” laws to kick into effect immediate abortion bans following the overturning of Roe v. Wade on Friday, these laws, in the works for more than a decade in some states, will likely kick off even more legal battles as states seek to restrict the use of prescription drug-based abortions.

Since Friday’s SCOTUS opinion to overturn Americans’ constitutional right to an abortion after almost 50 years, reproductive rights lawyers at Planned Parenthood and other organizations have already challenged these trigger laws in Utah and Louisiana. According to the Guttmacher Institute, other states with trigger laws that could take effect include Arkansas, Idaho, Kentucky, Mississippi, Missouri, North Dakota, Oklahoma, South Dakota, Tennessee, Texas, and Wyoming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

AstraZeneca's new Evusheld direct to consumer campaign aims to reach more immunocompromised patients.

As­traZeneca de­buts first con­sumer cam­paign for its Covid-19 pro­phy­lac­tic Evusheld — and a first for EUA drugs

AstraZeneca’s first consumer ad for Evusheld is also a first for drugs that have been granted emergency use authorizations during the pandemic.

The first DTC ad for a medicine under emergency approval, the Evusheld campaign launching this week aims to raise awareness among immunocompromised patients — and spur more use.

Evusheld nabbed emergency authorization in December, however, despite millions of immunocompromised people looking for a solution and now more widespread availability of the drug.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

Am­gen takes next step with its Chi­na am­bi­tions, out-li­cens­ing drugs to Fo­s­un Phar­ma

In a bid to increase its market share in China, Amgen has agreed to a partnership with a Shanghai biotech — a collaboration and out-licensing agreement for two of its drugs.

Amgen and Fosun Pharma announced a deal Monday in a bid to increase Amgen’s presence in the country. The stated goal so far is to commercialize Amgen’s blockbuster psoriasis drug Otezla alongside Parsabiv, a drug for secondary hyperparathyroidism in adults with chronic kidney disease and on a specific type of dialysis.

As court case looms, Bris­tol My­ers touts la­bel ex­pan­sion for Breyanzi

As Bristol Myers Squibb braces for a court battle over a costly delay — at least for Celgene shareholders — for its CAR-T lymphoma treatment Breyanzi, the pharma giant is touting a label expansion in the second-line setting.

Breyanzi, also known as liso-cel, snagged a win on Friday in adults with large B-cell lymphoma (LBCL) who: don’t respond to chemotherapy, or relapse within 12 months; don’t respond or relapse after 12 months; or are not eligible for hematopoietic stem cell transplant after chemo due to their age or comorbidities.

Deborah Dunsire, Lundbeck CEO

Af­ter a 5-year re­peat PhI­II so­journ, Lund­beck and Ot­su­ka say they're fi­nal­ly ready to pur­sue OK to use Rex­ul­ti against Alzheimer's ag­i­ta­tion

Five years after Lundbeck and their longtime collaborators at Otsuka turned up a mixed set of Phase III data for Rexulti as a treatment for Alzheimer’s dementia-related agitation, they’ve come through with a new pivotal trial success they believe will finally put them on the road to an approval at the FDA. And if they’re right, some analysts believe they’re a short step away from adding more than $500 million in annual sales for the drug, already approved in depression and schizophrenia.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.

A Mer­ck part­ner is sucked in­to the fi­nan­cial quag­mire as key lender calls in a note

Another biotech standing on shaky financial legs has fallen victim to the bears.

Merck partner 4D Pharma has reported that a key lender, Oxford Finance, shoved the UK company into administration after calling in a $14 million loan they couldn’t immediately make good on. Trading in their stock was halted with a market cap that had fallen to a mere £30 million.

“Despite the very difficult prevailing market conditions,” 4D reported on Friday, the biotech had been making progress on finding some new financing and turned to Oxford with an alternative late on Thursday and then again Friday morning.